Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents

Background— Concern regarding risk of late thrombosis after “off-label” treatment with drug-eluting stents has prompted increased use of bare-metal stents (BMS) in current practice. The sequelae of late BMS failures, however, have been poorly characterized. Methods and Results— We performed a retrospective study of 4503 consecutive patients treated with at least 1 BMS and dual antiplatelet therapy between 1994 and 2000. The cumulative incidence of stent thrombosis was 0.5% at 30 days (95% CI, 0.3% to 0.7%), 0.8% at 1 year (95% CI, 0.6% to 1.1%), and 2.0% at 10 years (95% CI, 1.5% to 2.5%). Risk of late (30 days to 1 year) and very late (>1 year) BMS thrombosis was increased among patients considered off label for drug-eluting stent use (P=0.024). When saphenous vein graft interventions were excluded, however, risk after off-label use was not significantly increased (P=0.23). Other correlates included vein graft intervention, prior myocardial infarction (MI), peripheral vascular disease, and ulcerated lesion (P<0.001). Mortality was markedly increased after late and very late BMS thrombosis, particularly during the first 30 days (hazard ratios, 22 [95% CI, 3.1 to 159] and 40 [95% CI, 15 to 107], respectively). The 10-year incidence of clinical restenosis was 18.1% (95% CI, 16.5% to 19.7%), presenting with MI in 2.1% (95% CI, 1.6% to 2.6%). Restenosis presenting with MI was associated with increased mortality compared with no restenosis (hazard ratio, 2.37; P<0.001) and with restenosis with a non-MI presentation (hazard ratio, 2.42; P<0.001). Conclusions— The incidence of BMS thrombosis and of MI caused by restenosis during extended follow-up is significant. Both complications are associated with mortality.

[1]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[2]  William Wijns,et al.  Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. , 2007, Circulation.

[3]  K. Ono,et al.  Histopathological findings of new in‐stent lesions developed beyond five years , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  S. Tsimikas,et al.  Drug-eluting stents and late adverse clinical outcomes lessons learned, lessons awaited. , 2006, Journal of the American College of Cardiology.

[5]  Giuseppe Musumeci,et al.  Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.

[6]  J. Lasala,et al.  Late stent thrombosis in the nonbrachytherapy population: A real phenomenon? , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  G. Davis,et al.  Myocardial infarction as a presentation of clinical in-stent restenosis. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[8]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[9]  S. Fichtlscherer,et al.  Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease , 2001, Circulation research.

[10]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[11]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[12]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[13]  Renu Virmani,et al.  Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans , 2003, Circulation.

[14]  M. Bell,et al.  Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. , 2002, Journal of the American College of Cardiology.

[15]  Deepak L. Bhatt,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[16]  K. Kent,et al.  Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.

[17]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[18]  Patrick W Serruys,et al.  New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.

[19]  Seiki Nagata,et al.  Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. , 2006, Journal of the American College of Cardiology.

[20]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[21]  W. Maisel Unanswered questions--drug-eluting stents and the risk of late thrombosis. , 2007, The New England journal of medicine.

[22]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.

[23]  William Wijns,et al.  A Cause for Concern , 2007 .

[24]  Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. , 2005, Journal of the American College of Cardiology.